DexCom (NASDAQ:DXCM) : 14 analysts are covering DexCom (NASDAQ:DXCM) and their average rating on the stock is 1.68, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. DexCom (NASDAQ:DXCM) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
DexCom (NASDAQ:DXCM) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $112 and the lowest price target forecast is $57. The average forecast of all the analysts is $87.6 and the expected standard deviation is $13.21.
For the current week, the company shares have a recommendation consensus of Buy.
DexCom (NASDAQ:DXCM): stock turned positive on Tuesday. Though the stock opened at $76.5, the bulls momentum made the stock top out at $78.3175 level for the day. The stock recorded a low of $76.22 and closed the trading day at $78.04, in the green by 2.81%. The total traded volume for the day was 843,317. The stock had closed at $75.91 in the previous days trading.
In an insider trading activity, Balo Andrew K, officer (EVP, Clinical, Regulatory) of Dexcom Inc, unloaded 55,000 shares at an average price of $75 on June 20, 2016. The total amount of the transaction was worth $4,125,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4, DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patients receiver and an application on the patients iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers, who can remotely monitor a patients glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpots data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.